Vlado Perkovic's Publications

• WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY

  Journal articles

  2023

  Kidney International Reports

• WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY

  Journal articles

  2023

  Kidney International Reports

• TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL

  Journal articles

  2023

  Journal of the American College of Cardiology

• Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply

  Journal articles

  2022

  The New England journal of medicine

• Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

  Journal articles

  2022

  European Heart Journal

• Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice

  Journal articles

  2022

  Heart Lung and Circulation

• Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

  Journal articles

  2022

  Cardiovascular Diabetology

• Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  Journal articles

  2022

  The Lancet

• Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin

  Journal articles

  2022

  Circulation

• Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin

  Conference Papers

  2022

  CIRCULATION

• Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

  Journal articles

  2022

  Journal of the American College of Cardiology

• Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

  Journal articles

  2022

  Diabetes Care

• Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease

  Journal articles

  2022

  Clinical Pharmacology and Therapeutics

• The ASCEND-ND trial: study design and participant characteristics

  Journal articles

  2022

  Nephrology Dialysis Transplantation

• Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

  Journal articles

  2022

  European Heart Journal

• Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

  Journal articles

  2022

  European Heart Journal

• Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

  Journal articles

  2022

  European Heart Journal

• CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

  Conference Abstracts

  2022

  NEPHROLOGY

• Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply

  Journal articles

  2022

  JAMA

• Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbAsub1csub and predicted risk of kidney failure

  Conference Abstracts

  2022

  DIABETOLOGIA

• Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

  Conference Abstracts

  2022

  DIABETOLOGIA

• Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

  Journal articles

  2022

  The Lancet Diabetes and Endocrinology

• Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

  Journal articles

  2022

  Journal of the American Heart Association

• Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

  Journal articles

  2022

  Diabetes Care